GABAergic neurons

GABAergic neurons are the primary inhibitory cell population in the central nervous system, responsible for the synthesis and release of the neurotransmitter gamma-aminobutyric acid (GABA) [1, 4]. These neurons are essential for maintaining the excitatory-inhibitory (E/I) balance within neural circuits, preventing the uncontrolled firing that leads to seizures and other excitotoxic states [3, 10]. GABAergic cells are highly heterogeneous and are often classified into subtypes based on their morphological features and the expression of calcium-binding proteins like parvalbumin or neuropeptides like somatostatin [6, 11]. Dysfunction of these neurons is a core component of the pathophysiology of epilepsy, schizophrenia, and anxiety disorders [8, 9]. While the neurons themselves are a cellular class, they house several high-value molecular targets, including GABA receptors (A and B), the GABA transporter (GAT-1), and the enzyme glutamic acid decarboxylase (GAD) [2, 5]. Pharmacological modulation of these components via benzodiazepines, barbiturates, or reuptake inhibitors is a standard therapeutic strategy to enhance inhibitory signaling and treat central nervous system disorders [5, 7, 12].

Other names

Inhibitory neuronsGABA-releasing neuronsGABAergic interneuronsGABA neuronsInhibitory interneurons

Pharmacological agents interact with the molecular components of GABAergic neurons by acting as positive allosteric modulators of ionotropic GABA-A receptors [5, 7], agonists of metabotropic GABA-B receptors [2], inhibitors of GABA transaminase to block catabolism (e.g., Vigabatrin) [1], or inhibitors of GABA transporters to prevent reuptake (e.g., Tiagabine) [4, 5].